

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				INT'L FILING NO.		PCT/US2004/026434	
				INT'L FILING DATE		August 10, 2004	
				APPLICANT		Bacus et al.	
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		PR60446USw	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	1.	WO 04/000094	12/31/2003	PCT			
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
	2.	ALBANELL et al., Activated Extracellular Signal-regulated Kinases: Association with Epidermal Growth Factor Receptor/Transforming Growth Factor $\alpha$ Expression in Head and Neck Squamous Carcinoma and Inhibition by Anti-Epidermal Growth Factor Receptor Treatments, <i>Cancer Research</i> 61:6506-6510 (2001).					
	3.	BROGNARD et al., Akt/Protein Kinase B is Constitutively Active in Non-Small Cell Lung Cancer cells and Promotes Cellular Survival and Resistance to Chemotherapy and Radiation, <i>Cancer Research</i> 61:3986-3997 (2001).					
	4.	CHEN et al., Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer, <i>Oncogene</i> 20:6073-6083 (2001).					
	5.	COCKERILL et al., Indazolylamino Quinazolines and Pyridopyrimidines as Inhibitors of the EGFR and C-erbB-2, <i>Bioorganic &amp; Med. Chem. Lett.</i> 11:1401-1405 (2001).					
	6.	GRANDIS et al., Levels of TGF- $\alpha$ and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival, <i>J. Nat. Cancer Inst.</i> 90(11):824-832 (1998).					
	7.	HOSHINO et al., Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors, <i>Oncogene</i> 18:813-822 (1999).					
	8.	JANES et al., Activation of the Ras signaling pathway in human breast cancer cells overexpressing <i>erbB-2</i> , <i>Oncogene</i> 9:3601-3608 (1994).					
	9.	RUSNAK et al., The Characterization of Novel, Dual ErbB-2/EGFR, Tyrosine Kinase Inhibitors: Potential Therapy for Cancer, <i>Cancer Research</i> 61:7196-7203 (2001).					
	10.	RUSNAK et al., The Effect of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines <i>In Vitro</i> and <i>In Vivo</i> , <i>Mol. Cancer Ther.</i> 1:85-94 (2001).					
	11.	TARI and LOPEZ-BERESTEIN, Serum predominantly activates MAPK and Akt kinases in EGFR- and ErbB2-over-expression cells, respectively, <i>Int. J. Cancer</i> 86:295-297 (2000).					
	12.	TENZER et al., The Phosphatidylinositol 3'-Kinase/Akt Survival Pathway is a Target for the anticancer and Radiosensitizing Agent PKC412, an Inhibitor of Protein Kinase C', <i>Cancer Research</i> 61:8203-8210 (2001).					
EXAMINER				/Sean Aeder/ (05/19/2008)		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							